Case Report: Late choroidal metastasis from hormone receptor-positive, HER2-negative breast cancer responsive to...

Distant metastatic breast cancer can occur years after initial diagnosis, with choroidal metastasis being a rare but significant manifestation. This case report presents a patient with a history of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) invasive ductal carcinoma (IDC) of the left breast, who developed late choroidal metastasis. The patient underwent systemic therapy with an aromatase inhibitor and cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor leading to regression of choroidal metastases. We also conducted a literature review of similar cases. External beam radiotherapy is the gold standard for management of choroidal metastases. However, it appears that first-line treatment with endocrine therapy and CDK4/6 inhibitors in patients with ER+ and HER2- breast cancer is likely effective for the treatment of choroidal metastases secondary to ER+/HER2- breast cancer and may allow a delay in the use of local invasive interventions.